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Abstract 
 
Background: Valid consent for treatment or research participation requires that an 
individual has decision-making capacity (DMC), which is the ability to make a specific 
decision. There is evidence that the psychopathology of schizophrenia can 
compromise DMC. The objective of this review was to examine the presence or 
absence of DMC in schizophrenia and the socio-demographic/psychopathological 
factors associated. 
 
Methods: We searched three databases Embase, Ovid MEDLINE(R), and PsycINFO 
for studies reporting data on the proportion of DMC for treatment and research (DMC-
T and DMC-R), and/or socio-demographic/psychopathological associations with ability 
to make such decisions, in people with schizophrenia and related illnesses. 
 
Results: 40 studies were identified. While high levels of heterogeneity limited direct 
comparison, meta-analysis of inpatient data showed that DMC-T was present in 48% 
of people.  Insight was strongly associated with DMC-T.  Neurocognitive deficits were 
strongly associated with lack of DMC-R and to a lesser extent DMC-T. With the 
exception of years of education, there was no evidence for an association with socio-
demographic factors. 
 
Conclusions: Insight and neurocognitive deficits are most closely associated with DMC 
in schizophrenia.  The lack of an association with socio-demographic factors dispels 
common misperceptions regarding DMC and characteristics such as age.  Although 
our results reveal a wide spectrum of DMC-T and DMC-R in schizophrenia, this could 
be partly due to the complexity of the DMC construct and the heterogeneity of existing 
studies. To facilitate systematic review research, there is a need for improvement 
within research study design and increased consistency of concepts and tools. 
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Introduction 
 
Consent for treatment or research  requires the individual to have the ability to make a 
decision, known as decision-making capacity (DMC) (Grisso and Appelbaum, 1998). 
Many legislative regions now use DMC to regulate treatment or research participation 
(Appelbaum, 2007, Nicholson et al., 2008).  
 
Non-affective psychotic illnesses such as schizophrenia and its symptoms can 
compromise DMC (Appelbaum and Grisso, 1995, Grisso et al., 1995, Grisso and 
Appelbaum, 1995).  Assessments of DMC for treatment (DMC-T) can result in 
substantial changes in a person’s experience of treatment: either autonomous decision 
making for oneself or decisions made by others.  In decisions regarding research 
participation lacking decision making capacity for research (DMC-R), or being deemed 
likely to lack it, may lead to ineligibility for research recruitment. 
  
Given that DMC is decision-specific, the information to be understood is different for 
each decision  (Jacob et al., 2013).  Therefore, the same individual may lack DMC for 
one decision but not another (Grisso and Appelbaum, 1998).   Furthermore, DMC also 
involves considering this information within the context of personal circumstances, 
beliefs, and values   Understanding lack of DMC in people with schizophrenia, the 
associated symptoms, to what extent loss is decision-specific and how individual 
context might effect DMC is of critical importance to all clinicians working with this 
mental disorder.  
 
DMC is a complex construct. The underlying abilities, e.g. understanding or reasoning, 
can be measured as dimensional or categorical (such as by applying a cut-off). In 
clinical and legal practice a decision must be made that the person has, or lacks, the 
ability for DMC, making it a binary judgement.    
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Different legislative regions have separate legal definitions for the abilities which are 
jointly necessary for DMC. In England and Wales the legal test is defined by the Mental 
Capacity Act 2005 (MCA) and requires the ability to: 'understand’ the information 
relevant to a decision; 'retain' it; 'use or weigh' the information to arrive at a decision; 
and 'communicate' that decision.  Many US states use a similar model -  the ‘four factor 
model’ of ‘understanding’, ‘appreciation’, ‘reasoning’, and ‘expressing a choice’ 
(Appelbaum and Grisso, 1995, Grisso et al., 1995, Grisso and Appelbaum, 1995). The 
four factors of the MCA are viewed as largely synonymous with the US four factors, 
with ‘use or weigh’ incorporating ‘appreciation’ and ‘reasoning’ (Owen et al., 2009a).  
Assessments of DMC for legal and medical consent are made by clinicians or the court 
based on the relevant legal test.  Such assessments are, ultimately, the ‘gold standard’ 
of DMC assessment and, although the court is the final arbitrator, the assessment 
process itself is delegated mainly to clinicians.   
 
Research into DMC has therefore measured DMC in one of three ways: 
 
1) ‘Dimensional scores’: use of structured tools to psychometrically assess 
performance within individual domains of abilities deemed core to DMC (such 
as the ‘four factor model’) to return a score for each dimension. 
2) ‘Cut-off standard’: applying a cut-off or scoring algorithm to ‘dimensional 
scores’. 
3) ‘Judgement standard’: clinical or court assessment of DMC returning a binary 
judgement.  This may or may not be guided by legal criteria and dimensions to 
be assessed (such as the MCA in the UK or the ‘four factor model’ in the US). 
 
Each approach has both advantages and limitations:   The ‘cut-off standard’ and 
‘dimensional scores’ are primarily for research use, and allow for a more detailed 
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exploration of symptoms contributing to DMC vulnerability than the ‘judgement 
standard’ permits.   The ‘judgement standard’ is the standard of DMC in clinical and 
legal practice, although it may be guided by the other two tools.  A highly influential 
study, the MacArthur Treatment Competence study (Appelbaum and Grisso, 1995, 
Grisso et al., 1995, Grisso and Appelbaum, 1995), developed a set of tools for 
assessing DMC-T using ‘dimensional scores’ based on the ‘four factor model’.  These 
were subsequently condensed into the MacArthur Competence Assessment Tool for 
Treatment (MacCAT-T) (Grisso et al., 1997) and then adapted for decisions regarding 
Clinical Research (MacCAT-CR) (Appelbaum and Grisso, 2001).  These tools led to 
an explosion of research into DMC, with many studies measuring DMC using 
‘dimensional scores’. 
 
The objective of the present review was to explore proportions and clinical associations 
of DMC in people with schizophrenia using these three standards (for the purpose of 
clarity we use the term ‘schizophrenia’ to refer to non-affective psychosis including, but 
not limited to, schizoaffective disorder, delusional disorder, transient psychotic 
episodes etc.).  Our research questions were:   
 
1) What proportion of people with schizohrenia have DMC for specified civil decisions 
(such as treatment or participation in research) in specified settings (e.g. inpatient, 
outpatient)?   
 
2) What are the associations with DMC for civil decisions? We pre-specified 
associations of interest as positive symptoms, negative symptoms, general symptoms 
of psychosis, neurocognitive symptoms, affective symptoms, awareness of illness 
(insight) and socio-demographic variables (age, sex, ethnicity and educational level). 
To our knowledge there have been two previous systematic reviews into DMC in 
schizophrenia, rather than in conjunction with other diagnoses such as dementia or 
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bipolar affective disorder (Jeste et al., 2006, Wang et al., 2016).  However, unlike ours, 
both these reviews focused primarily on a comparing dimensional DMC scores in those 
diagnosed with schizophrenia and in ‘normal controls’, finding  that people with 
schizophrenia did less well. 
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Methods 
 
Eligibility Criteria  
 
We included studies published in English which assessed the DMC of samples of 
people over the age of 18 diagnosed with non-affective psychosis, as defined by: f20-
29 ICD-10 (World Health Organization., 1993) or 295, 297, 298 DSM-IV (American 
Psychiatric Association., 1994).  We included studies measuring DMC or domains of 
DMC using the three approaches described above: the ‘judgement standard’; ‘cut-off 
standard’; or ‘dimensional scores’.  We excluded non-civil assessments of DMC (such 
as fitness to plead). 
 
 
Search 
 
We used OVID to search Embase, Ovid MEDLINE (R), and PsycINFO. Our search 
string was chosen following several trial iterations of searches to maximise the 
sensitivity of the search, given that ‘capacity’ has multiple homonyms. Our final search 
string was a title and abstract search of: (capacity or competence or competency or 
'decision making' or 'decision-making') AND (schizophrenia or psychosis or 'mental 
illness' or 'mental disorder' or psychotic).  The search was completed on 16/02/2015, 
with results exported to Endnote X7.  The citation search was performed on 
17/07/2015,  with all steps in both searches performed by BS. 
 
References reporting data from the same study were excluded unless the samples 
were mutually exclusive.  Exclusion occurred at the data extraction stage and following 
correspondence with the authors.  In these cases the reference best suited to the 
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review was selected by BS for retention within the final selection.  In addition, if multiple 
references reported complementary analyses of the same sample they were treated 
as one reference in the final analysis.  
 
Data collection and data items 
 
BS extracted all data using a data extraction form which specified: population studied 
and associated demographics; nature of decision for which DMC was assessed 
(whether it was for a decision related to the present disorder, such as treatment for 
schizophrenia rather than treatment for another unrelated medical condition, and, in 
the case of DMC-R, whether it was for hypothetical or real study involvement); outcome 
of the DMC assessment (proportions from studies using ‘judgement standard’ and ‘cut-
off standard’); effect sizes for any associations between DMC and variables of interest.  
Only summary data, rather than data on individual items of tools was extracted from 
studies.  The only exception was item G12 on the Positive and Negative Syndrome 
Scale (PANSS) (Kay et al., 1987) ‘lack of judgement and insight’, which we chose to 
include, given that this was the primary measure of insight used in several studies. 
 
 
Statistical analysis 
 
 
Confidence intervals (95%) were calculated for proportions of DMC following 
‘judgement standard’ or ‘cut-off standard’ using the Wilson score interval.  Odds ratios 
and correlation coefficients were converted into effect sizes (ES) for our principal 
summary measure.  Given that some studies were able to detect very small ES, we 
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modified the Cohen criteria (Cohen, 1992) to: >0 to 0.3 small ES, 0.3 medium ES, 
and 0.5 large ES.  
 
We aimed to meta-analyse the proportions of people with DMC as measured by the 
‘judgement standard’.  For studies to be eligible for the meta-analysis for DMC, they 
needed to test DMC for similar decisions (e.g. DMC-T for treatment of the present 
disorder) within a homogenous setting (e.g. solely inpatients or outpatients) and 
without other factors likely to bias the result as decided by the authors (e.g. not 
systematically excluding detained or severely unwell people).  Meta-analysis of 
proportions was performed using STATA 14 (StataCorp).  Given the residual 
heterogeneity between studies, a random effects model was used.  
 
Risk of bias assessment 
 
To our knowledge there has been no prior attempt to appraise quality in DMC studies.  
We considered certain factors to be important based on our clinical experience when 
reviewing studies on DMC.  These included: 1) the exact nature of the decision for 
which DMC is being assessed (whether it was real, hypothetical, related to the present 
disorder - schizophrenia or wholly unrelated), as this may impact on effect of symptoms 
of schizophrenia on DMC (for example, whether insight into illness is relevant to the 
decision, whether the decision was cognitively demanding, etc.); 2) homogenous 
setting of recruitment (either all inpatients or outpatients and thus controlling for hidden 
confounders in these settings); 3) ability to recruit people with a range of severity of 
illness within a specified setting, given that this would likely impact on DMC (for 
example, were people deemed to be ‘too unwell’ systematically excluded from the 
sample).   We developed a risk of bias assessment based on these which 
demonstrated critical risk of bias for the majority of studies (available from the authors 
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on request).  As we wanted to provide an overview of the literature, we decided to 
exclude a risk of bias assessment from this review, but comment further on the quality 
of research in the discussion.  
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Results 
 
Of 11658 references screened from titles, 682 references went to full text review, and 
40 met our inclusion criteria (see figure 1) (Chiu et al., 2014, Bean et al., 1994, Veliz 
and James, 1987, Weinstock et al., 1984, Moye et al., 2008, Wong et al., 2000, 
Bellhouse et al., 2003, Vollmann et al., 2003, Owen et al., 2009a, Skipworth et al., 
2013, Cairns et al., 2005, Stroup et al., 2005, Dunn et al., 2007, Jeste et al., 2009, 
Candilis et al., 2006, Candilis et al., 2008, Moser et al., 2002, Palmer and Jeste, 2006, 
Kovnick et al., 2003, Palmer et al., 2005, Lan et al., 2013, Carpenter Jr et al., 2000, 
Moser et al., 2006, Eyler et al., 2007, Moser et al., 2005, Wong et al., 2005, Palmer et 
al., 2004, Capdevielle et al., 2011, Raffard et al., 2013, Grisso et al., 1997, Appelbaum 
and Grisso, 1995, Grisso et al., 1995, Grisso and Appelbaum, 1995, Di and Cheng, 
2013, Norko et al., 1990, Koren et al., 2005, Fischer et al., 2013, Cohen et al., 2004, 
Linder et al., 2012, Eyler et al., 2005, Owen et al., 2011, Kavanagh et al., 2008, Valletto 
et al., 2002, Srebnik et al., 2004, Kumar et al., 2013, De Marco et al., 2010).  A clinician 
with expertise in the field (GS) performed an independent review of all 682 references 
applying the inclusion and exclusion criteria. Inter-rater reliability between BS and GS 
was high (K=0.80).  Disagreements were resolved following discussion between BS 
and GS, while any unresolved disputes went to GO as final arbiter (n=3).   
 
Heterogeneity between studies was high, with considerable variation in study design, 
population, measurements and the nature of decision for which DMC was assessed 
(see table 1).  Many studies reported only partial data for the outcomes of interest, 
while the studies assessing DMC using a ‘judgement standard’ rarely presented any 
associations with our pre-specified variables of interest.  Results from all studies and 
characteristics are available in the supplemental data table.  Most studies assessed 
psychopathology using either the PANSS or Brief Psychiatric Rating Scale 
(BPRS)(Overall and Gorham, 1962).  Many studies used a range of diverse individual 
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neurocognitive sub-tests from various test batteries (such as the Wechsler Adult 
Intelligence Scale - III (WAIS-III (Wechsler, 1997)) without a summary score provided.  
These individual results were not extracted, given the difficulties in direct comparison 
between studies.   
 
Given the limited numbers of studies investigating decisions other than DMC-T and 
DMC-R (n=5), we limited our review to treatment and research (n=40).  These five 
studies considered DMC for organ donation (De Marco et al., 2010), making a 
psychiatric advance directive (Kumar et al., 2013, Valletto et al., 2002, Srebnik et al., 
2004), and DMC to manage one’s own finances (Barrett et al., 2009). 
 
Performance on different standards of Decision-Making Capacity (DMC) 
 
Proportion of DMC-T in studies using ‘judgement standard’ and ‘cut-off standard’ 
 
Ten studies reported the proportion of DMC-T amongst participants when using the 
‘judgement standard’ (Bean et al., 1994, Bellhouse et al., 2003, Owen et al., 2009a, 
Cairns et al., 2005, Owen et al., 2011, Veliz and James, 1987, Chiu et al., 2014, 
Vollmann et al., 2003, Weinstock et al., 1984, Wong et al., 2000, Skipworth et al., 
2013), while three studies used the ‘cut-off standard’ (Di and Cheng, 2013, Norko et 
al., 1990, Moye et al., 2008).  Characteristics and results from all studies providing 
data on ‘judgement standard’ or ‘cut-off standard’ of assessment are presented in table 
2 (Chiu 2014 and Norko 1990 are excluded and considered separately below).  The 
range of proportions of DMC-T reported by all studies is large (11-100%) and there is 
significant heterogeneity between studies: six studies recruited from inpatient settings 
(Veliz and James, 1987, Bean et al., 1994, Bellhouse et al., 2003, Owen et al., 2009a, 
Owen et al., 2011, Cairns et al., 2005, Di and Cheng, 2013, Vollmann et al., 2003), 
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one from outpatients (Moye et al., 2008), two from mixed inpatients and outpatient 
settings (Wong et al., 2000, Skipworth et al., 2013), and one from a general medical 
hospital setting (Weinstock et al., 1984).  Seven studies assessed DMC-T for a 
decision that was related to the disorder (hospital admission or treatment for 
schizophrenia) (Veliz and James, 1987, Bean et al., 1994, Bellhouse et al., 2003, 
Skipworth et al., 2013, Owen et al., 2009a, Owen et al., 2011, Cairns et al., 2005, Di 
and Cheng, 2013, Vollmann et al., 2003); two assessed DMC-T for medical treatment 
unrelated to schizophrenia (Weinstock et al., 1984, Moye et al., 2008); and one 
assessed DMC-T for treatment with an unclear relationship to schizophrenia (Wong et 
al., 2000).  Two studies assessed DMC-T as a naturalistic study in which people were 
recruited following concerns regarding a lack of DMC-T having been raised (Weinstock 
et al., 1984, Veliz and James, 1987). 
 
It was only within the set of studies recruiting from inpatient settings that there were 
two or more studies sufficiently comparable with each other in terms of recruitment 
setting and nature of decision for which DMC-T was assessed in order to be eligible to 
undergo meta-analysis (Bean et al., 1994, Bellhouse et al., 2003, Owen et al., 2009a, 
Cairns et al., 2005, Owen et al., 2011, Di and Cheng, 2013).  These studies assessed 
DMC-T for psychiatric admission and/or treatment in hospital with medication or ECT; 
three were UK based and used the MCA legal standard.  The range of people with 
DMC-T was 26-67%.  A meta-analysis of proportions using a random effects model 
indicated high heterogeneity (I2 – 84.41%) and a pooled proportion of 48% (95CI 29-
66%) with DMC-T (see figure 2).   
 
Of the two studies considered separately: Norko 1990 (Norko et al., 1990) , used a 
range of ‘cut-offs’ based on combinations of ‘dimensional scores’, and found that DMC 
varied between 45-80%, depending on the precise cut-off used.  Chiu 2014 (Chiu et 
al., 2014) reported the characteristics of people given Electro-Convulsive Therapy 
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(ECT) without consent, dichotomising the groups into people without DMC-T given 
ECT and people with DMC-T given ECT despite objecting.  In those having ECT 
without consent, n=13, 76% (95CI 53-90%) lacked DMC-T.   
 
Proportion of DMC-R from ‘judgement standard’ and ‘cut-off standard’ 
 
One study (Dunn et al., 2007) tested DMC-R concerning a hypothetical decision 
related to schizophrenia in a mixed population of inpatients and outpatients.  It used 
three ‘cut-off standards’, ‘least’; ‘intermediate’; and ‘most’, (the ‘Dunn standard’) and 
found that 92%, 81%, 43% met their standards for each of these respectively.  Another 
study used a ‘judgement standard’ to test DMC-R amongst older outpatients (Jeste et 
al., 2009) and found that 47% of those undergoing ‘routine consent’ had DMC-R.  
 
‘Dimensional scores’ and DMC-T/DMC-R 
 
Five studies reported ‘dimensional scores’ from MacCAT-T sub-scales (Grisso et al., 
1997, Wong et al., 2005, Palmer et al., 2004, Capdevielle et al., 2011, Koren et al., 
2005), and thirteen studies reported ‘dimensional scores’ from MacCAT-CR sub-
scales (Dunn et al., 2007, Jeste et al., 2009, Candilis et al., 2006, Candilis et al., 2008, 
Moser et al., 2002, Palmer and Jeste, 2006, Kovnick et al., 2003, Palmer et al., 2005, 
Lan et al., 2013, Carpenter Jr et al., 2000, Moser et al., 2006, Eyler et al., 2007, Moser 
et al., 2005, Stroup et al., 2005).  These were all reported as arithmetic means and 
standard deviations.  One study provided ‘dimensional scores’ from the precursor tools 
to the MacCATs (Appelbaum and Grisso, 1995, Grisso et al., 1995, Grisso and 
Appelbaum, 1995).  Given that the data are consistently reported as highly skewed, a 
formal statistical comparison between the studies cannot be made, while study 
heterogeneity already renders comparison of questionable usefulness. 
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Associations 
 
Most associations were reported as correlations with ‘dimensional scores’ based on 
the ‘four factor model’.  These are summarised and presented along with associations 
with the ‘judgement standard’ in table 3.   
 
Associations with DMC-T 
 
With the exception of insight, neurocognition, and socio-economic status (which 
includes a measure of years of education) most studies found no associations with 
DMC-T measured using either ‘dimensional scores’ or the ‘judgement standard’.  There 
was no heterogeneity between direction of associations when they were found by 
studies.   
 
There was strong evidence for a negative association between lack of insight and 
DMC-T (medium to large ES), and positive association between better neurocognitive 
performance and DMC-T (medium ES).  These associations covered a range of 
different dimensions with no discernible pattern for individual abilities such as 
‘understanding’.   
 
The lack of any association with most socio-demographic variables (age, gender, race) 
is notable.  There was a positive association in one study with higher socio-economic 
status and DMC-T, and weak evidence for a positive association for more years of 
education and DMC-T, especially with ‘Understanding’ (small to large ES).   
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With regards to symptoms of psychosis and DMC-T, there was some evidence for a 
negative association of PANSS total symptoms and PANSS negative symptoms with 
‘understanding’ (medium to large ES).  There was little evidence for a possible negative 
association of PANSS positive and PANSS general symptoms with dimension scores; 
overall, the majority of studies did not find any associations.  One study reported on 
associations with BPRS factors.  These are not included in the summary table 
(Appelbaum and Grisso, 1995, Grisso et al., 1995, Grisso and Appelbaum, 1995) but 
are in the supplemental data table, and did not differ from the general pattern of the 
findings of associations of psychotic symptoms with DMC-T.  No associations were 
found with affective symptoms. 
 
Associations with DMC-R 
 
The associations with DMC-R were similar to DMC-T with a few notable exceptions.  
Again, there was no heterogeneity between direction of associations when they were 
found by studies.  As with DMC-T, other than one multi-centre study (Stroup et al., 
2005), which reported negative associations between DMC-R and both ‘non-white’ 
ethnicity (small ES) and age and ‘reasoning’ (small ES), all studies found no 
associations with socio-demographics and DMC-R.  Again there was weak evidence 
for a positive association for more years of education and DMC-R (small to large ES).   
 
There was evidence for a positive association of better neurocognitive performance 
and DMC-R, which was much stronger than for DMC-T (small to large ES).  By 
contrast, the associations with insight and DMC-R were fewer and of smaller ES than 
with DMC-T (small to medium ES) 
 
There was a range of negative associations with DMC-R and measures of psychotic 
symptoms (PANSS scores and BPRS - small to large ES), which appears stronger 
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than with DMC-T, and perhaps not as specific to ‘understanding’.  Unlike DMC-T, there 
was also evidence for a negative association between PANSS general and PANSS 
negative symptoms with dimension scores.  Two studies reported on associations with 
BPRS factors (again not included in the summary table but are included in the 
supplemental data table) (Carpenter Jr et al., 2000, Kovnick et al., 2003)  These results 
did not substantially differ from the general pattern of the findings of associations of 
psychotic symptoms with DMC-R.   
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Discussion 
 
DMC-T versus DMC-R in schizophrenia 
 
Following meta-analysis, DMC-T, when measured by the ‘judgement standard’ was 
present in 48% of people receiving inpatient treatment for schizophrenia.  The range 
of the proportion with DMC-T was wide (26-67%).  Heterogeneity between both 
samples and different decisions for which DMC was assessed was high.  Outside of 
the analysis of DMC-T restricted to inpatient populations, it is difficult to draw any other 
distinct conclusions, using either ‘judgement standards’ or ‘cut-off standards’, beyond 
the finding that there is a wide range of DMC-T and DMC-R proportions in different 
samples of people with schizophrenia.   
 
There was little evidence that socio-demographic factors had an impact on DMC-T or 
DMC-R. The lack of association between DMC and basic demographics is both a 
reassuring and an important finding, given that DMC measurement outcomes should 
not, in principle, be influenced by age, gender, or ethnicity.  It runs counter to common 
misconceptions or presumptions that might be made regarding a lack of decision-
making capacity with certain demographic characteristics such as age.  Nevertheless, 
there was some weak evidence of an association with greater years of education.  
 
While there was strong evidence of an association between greater insight and DMC-
T, evidence of a similar association with DMC-R was much weaker.  Insight is a clinical 
concept which does not feature explicitly in the legal tests for DMC (although it is 
arguably subsumed within ‘appreciation’). The relation between insight and DMC 
poses particular conceptual difficulties because (Owen et al., 2009b)  a key component 
of a person’s autonomy is the right to refuse treatment when one has DMC.  In effect, 
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this means that the individual, whose decision-making is unimpaired, has the right for 
their disagreement with their clinician concerning the nature or treatment of their illness 
to be respected.  Yet lack of insight is a clinical phenomenon which comprises non-
acknowledgement of illness (David, 1990), due to a specific pathological process of 
the illness itself, and which often manifests itself as treatment refusal.  A judgement as 
to whether treatment refusal stems from the values and beliefs of someone with DMC 
or from lack of insight depends, primarily, on the judgement of the clinician (Owen et 
al., 2009b).  In the context of a person with a severe mental illness who is refusing 
treatment, there are understandable legal concerns if treatment refusal is equated with 
lack of DMC-T.  At the same time, lack of insight is a common and core element of 
psychosis (David, 1990), which can, as our review demonstrates, have a substantial 
impact on DMC.  These conceptual complexities are a natural corollary of mapping a 
medico-legal test onto clinical concepts.     
 
The finding of associations between total symptoms (measured as PANSS total score 
or BPRS), negative symptoms and dimension scores is as we might expect, although 
it is curious that evidence is less convincing for DMC-T than DMC-R. The lack of 
association between positive symptoms and dimension scores in DMC-T and DMC-R 
is an interesting finding, which runs counter to anecdotal clinical experience and 
requires further investigation.  These findings may be due to few participants with 
severe positive symptoms of psychosis being recruited for studies - many studies 
systematically excluded severely unwell people, either directly (through requiring 
vetting from the treating clinician), or indirectly (through recruiting in stable outpatient 
settings or setting a threshold of understanding or DMC for involvement in the primary 
study itself).  Another possibility is that severe positive symptoms themselves (such as 
persecutory delusional beliefs) may result in participation refusal.   
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Given that studies investigating DMC are vulnerable to this selection bias, we consider 
it important that studies are designed to recruit from homogenous settings or disorders 
and minimise selection bias for participants with severe illness or lacking DMC-R for 
the study itself.  A few studies have tackled this by collecting data on non-participants 
(Cairns et al., 2005, Owen et al., 2009a, Owen et al., 2011, Skipworth et al., 2013), but 
none have presented data on the symptom profile of non-participants in order to 
investigate further the lack of reported associations with DMC and positive symptoms.  
 
There was evidence that better neurocognitive performance was positively associated 
with DMC-T.  The evidence for this association in DMC-R was stronger, wherebetter 
neurocognitive performance was highly positively associated with ‘understanding’ and, 
to a lesser extent, with ‘appreciation’ and ‘reasoning’.  This could suggest that a 
decision about participation in research presents a greater cognitive burden than DMC-
T.  If this is the case, it has implications for how information should be presented to 
potential participants.  There is already evidence that educational (Dunn et al., 2002) 
and multimedia interventions (Jeste et al., 2009) can improve DMC-R in people with 
psychosis, mainly through enhancing ‘understanding’.  An alternative possibility is that, 
whereas a DMC-R testing paradigm is likely to present new information, within a DMC-
T study, ‘understanding’ may already have been supported through treatment 
discussions in years of clinical interactions. 
 
Methodological limitations 
 
Sample size between studies varied considerably, with the exception of one outlier 
study with n=1447, the range was n=2 to 192 with a median of 37.5, interquartile range 
42.  The majority of studies did not provide information on sampling frames and 
recruitment rates.  Although some provided information on non-participants (Skipworth 
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et al., 2013, Owen et al., 2009a, Owen et al., 2011, Cairns et al., 2005),this was for 
people of all diagnoses and hence could not be used specifically to refer to people with 
schizophrenia. 
 
Inappropriate statistical analyses were often employed in source publications. Within 
the DMC-T studies there were many studies with substantial biases or study specific 
features, such as the assessment of DMC-T for unrelated medical treatment or the 
restriction of sampling to those referred for a secondary opinion of DMC-T or those 
refusing treatment (see table 1 and supplemental data table).    
 
The review was limited by significant heterogeneity between studies, with differences 
between the outcome tools used, the decisions in relation to which DMC was assessed 
and the sampled populations.  For the analysis of DMC proportions, such differences 
were managed through stratifications using narrow inclusion criteria.  For the analysis 
of factors associated with DMC, given the extensive differences between all studies, 
stratification of analysis was not possible and all studies were therefore considered.  
Accordingly, due to possible confounders, we would recommend that these results are 
interpreted with caution. 
 
The decision-specificity of DMC is an importance source of the heterogeneity within 
the literature.  Even for clearly defined decisions around, for example, treatment for 
schizophrenia, the precise nature of the decision, such as Electro-Convulsive Therapy 
versus antipsychotic treatment with clozapine, may lend itself to different vulnerabilities 
in the different abilities that make up DMC.  While cognitively demanding decisions 
may require better performance on ‘understanding’ and ‘reasoning’ ,there is limited 
ability to compare the dimensional measures accordingly between studies.   
 
 Page 23 of 47 
The nature of the decision in relation to which DMC-R was tested requires special 
comment.  It is important to point out that many of the DMC-R studies tested decisions 
relating to research which could not be considered as schizophrenia-specific, but 
which concerned a generic treatment, aimed at a general population.  Several tested 
DMC-R concerning a trial of an experimental drug which may help cognitive deficits, 
both in schizophrenia and in normal ageing.  This decision, therefore, related to non 
schizophrenia-specific therapeutic research, where the salience of the decision to their 
present symptoms would vary substantially between participants and where the role of 
insight and other factors was unclear and not homogenous. The contribution of these 
studies to understanding DMC-R in schizophrenia in relation to therapeutic research 
for schizophrenia is thus unclear.  Decisions around research participation for 
therapeutic or non-therapeutic research may also pose different challenges, given the 
different risk/benefit profiles for the individual, and may therefore further complicate 
direct comparison between studies.  
 
As a consequence there remains a need to unpick which what abilities are global, 
impacting decision-making in general, and which are specific to the particular decision 
in hand.  We hypothesise that lack of insight into one’s illness would be relatively 
circumscribed to decisions around treatment or life consequences of the functional 
deficits of the illness through impact on ‘appreciation’, compared to symptoms such as 
‘thought disorder’ which may affect decision making more generally through impact on 
‘understanding’. 
 
The effect of publication bias on this review is unclear.  Funnel plots are difficult to do 
with this data but as most studies report simple proportions and/or multiple association 
analysis there are no strong reasons to suspect publication bias.  
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Categorical versus dimensional measures of DMC 
 
The majority of studies we found used ‘dimensional scores’ for their measurements of 
DMC.  The ‘judgment standard’ when used was used in isolation or  guided by tools 
using ‘dimensional scores’.  
 
Dimensional measures of DMC take an overly siloed view of the DMC construct, and 
it is likely these abilities are not independent of each other.  It is clear from our work 
that poor performance on different individual measures can impact others (if there are 
profound deficits on ‘understanding’, then there will be resultant deficits on 
‘appreciation’ or ‘use or weigh’; conversely in people with low insight this can be a total 
barrier to discussing the nature of their illness, even in abstract, and result in serious 
doubts about their resultant ‘understanding’).  This creates a hierarchical element to 
dimensional measures of DMC, in that sufficient performance on one ability is pre-
requisite to performance on other abilities. 
 
Dimensional measures can in some situations be relatively insensitive to deficits that 
categorical measures can detect.  Some elements of psychopathology can be highly 
circumscribed, and have marked impact on DMC as measured by a categorical 
standard, but relatively less impact on dimensional measures.   For example, an 
isolated delusional belief that participation within a research study will cure the 
participant of all illness may result in partially reduced scores on ‘appreciation’ and 
‘reasoning’ when assessed using the framework of the MacCAT-CR, but a clear lack 
of DMC-R when using a ‘judgement standard’.  Given the limitations to using 
dimensional measures in isolation, we recommend that future research employ both 
dimensional and judgement measures of DMC.  
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Conclusions 
 
We found that a significant proportion of people with schizophrenia, even on inpatient 
wards, have DMC, that DMC is associated with clinically relevant variables, such as 
insight and neurocognitive performance, and that DMC is not related to socio-
demographic factors.   
 
There have been many studies investigating DMC in schizophrenia in the past two 
decades.  To our knowledge, this is the most methodologically rigorous attempt to 
synthesise the findings from these studies, and one that was not limited to one 
standard of assessment of DMC or one type of decision for which DMC was assessed 
such as DMC-T or DMC-R.  This review is the first to overview the field and draw broad 
conclusions regarding the proportion and associations of DMC in schizophrenia and 
compare and contrast these for DMC-T and DMC-R.  It is clear, however, that the 
complexity of the DMC construct resulting from its decision-specificity and the 
dimensional and categorical approaches to measuring it renders the literature diverse.  
Arguably it is in disarray.  In order to develop our understanding of DMC in 
schizophrenia future quantitative research should involve comparative studies of DMC, 
using both dimensional and categorical measures, and provide data on non-
participants and sampling-frames.  Otherwise the time and decision-specific nature of 
DMC may lead to study-specificity, which renders systematic review impossible.    
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Figure 2 Meta-analysis of proportions of patients with DMC-T 
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Table 1 Main characteristics of studies 
 
 
 
DMC-
T or 
DMC-
R 
Standard 
used 
Decision 
related to 
schizophrenia 
Population 
setting 
Decision to be made by 
participant 
Format of assessment Associations reported Other Features Title 
DMC-T 
 
Expert 
Judgement 
Related 
Mixed 
Current psychiatric treatment with 
medication. 
Clinical assessment under the 
critera of the MCA 2005 and 
structured using the MacCAT-T. 
 
Mixed inpatients and outpatients under forensic 
services 
Skipworth 2013 
Inpatients 
Treatment in hospital with ECT. 
Clinical assessment (no further 
details). 
 Inpatients requiring ECT. Bean 1994 
Clinical assessment (no further 
details). 
 Patients who received ECT without consent. Chiu 2014 
Current psychiatric treatment. 
Clinical assessment (no further 
details). 
 
Referred to the Court for determination of lack of 
competency to refuse or consent to treatment 
forensic population. 
Veliz 1987 
Current admission and psychiatric 
treatment. 
Clinical assessment under the 
criteria of the legal precursor to the 
MCA and structured according to 
this. 
  Bellhouse 2003 
Current psychiatric treatment with 
medication. 
Clinical assessment under the 
criteria of the legal precursor to the 
MCA and structured and structured 
using the MacCAT-T. 
  Cairns 2005 
Either current admission or 
psychiatric treatment in hospital. 
Clinical assessment under the 
criteria of the MCA and structured 
using the MacCAT-T. 
SAI, BPRS.  Owen 2009/11 
Unrelated N/A 
Physical health treatment in a 
medical hospital. 
Clinical assessment using criteria 
based on early precursors to the 
four factor model, unstructured. 
 
Medically unwell in a physical health hospital 
referred for determination of DMC-T for medical 
treatment. 
Weinstock 1984 
Unclear Mixed Routine blood test. 
Clinical assessment under the 
criteria of the legal precursor to the 
MCA and structured according to 
this. 
 Decision for a blood test  - unclear degree related. Wong 2000 
Cut-off 
Related Inpatients 
Current psychiatric treatment. SSICA. Socio-demographics. 
Guardian also needed to agree in order to 
participate in study. 
Di 2013 
Current admission and psychiatric 
treatment. 
Tool assessing early precursors to 
the four factor model. 
 No detained patients. Norko 1990 
Unrelated Outpatients 
Hypothetical medical vignette 
involving a toe amputation or 
femoral bypass in non-healing toe 
ulcer. 
ACCT.  ≥ 60 years old. Moye 2008 
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Four Factor 
Scores 
Related 
Outpatients 
Current psychiatric treatment with 
atypical antipsychotic medication. 
MacCAT-T. 
PANSS, BRPS, DRS, socio-
demographics. 
Outpatients, although most living at community 
assisted living facilities. ≥ 40 years old. 
Palmer 2004 
Current psychiatric treatment. MacCAT-T. 
SUMD, PANSS, BDI, socio-
demographics. 
No treatment changes for the past month. Capdevielle 2009 
Current psychiatric treatment with 
antipsychotic medication. 
MacCAT-T. PANSS, BDI, socio-demographics. No treatment changes for the past month. Raffard 2013 
Inpatients 
Current psychiatric treatment. 
MacCAT-T precursors BPRS, VCF, socio-demographics. 
Clinicians requested really unwell people to not be 
recruited. 
Grisso 1995 
MacCAT-T. BRPS, socio-demographics.  Grisso 1997 
MacCAT-T.  
Within two weeks of admission when clinician has 
determined them able to cooperate. 
Koren 2005 
Maintenance antipsychotic 
treatment following discharge from 
hospital. 
MacCAT-T. 
G12 PANSS insight, PANSS, MADRS, 
socio-demographics. 
Before discharge from hospital. Wong 2005 
Cut-off & Expert 
Judgement 
Related Inpatients 
Current psychiatric treatment with 
medication. 
Clinical assessment under the 
criteria of the four factor model, 
unstructured, MacCAT-T. 
Socio-demographics. No detained patients. Vollmann 2003 
 
 
 
        
DMC-R 
Cut-off Related 
Outpatients 
RCT of adjunctive therapy to usual 
antipsychotic regimen. 
mESC. BRPS, MMSE. 
Already recruited to the parent study (deemed to 
have DMC-R). 
Fischer 2013 
Mixed 
RCT of atypical antipsychotic 
medication. 
MacCAT-CR. 
BIQ, PANSS, HAM-D, neurocognitive Z 
score, DRS, socio-demographics. 
Mixed outpatient and inpatients, including board and 
care homes. Aged ≥50. 
Dunn 2007 
Four Factor 
Scores 
Related 
Outpatients 
fMRI study of decision-making 
capacity. 
MacCAT-CR.  
Outpatient study recruiting from board and care 
homes. 
Eyler 2005 
Mixed 
RCT of antipsychotic medication. MacCAT-CR. BPRS, RBANS.  Carpenter 2000 
CATIE study (naturalistic 
antipsychotic treatment study). 
MacCAT-CR. 
PANSS, neurocognitive Z score, socio-
demographics. 
Mixed inpatients and outpatients already recruited to 
the CATIE study (having suboptimal antipsychotic 
treatment) and passing a MacCAT-CR based DMC-
R threshold (U ≥ 16). 
Stroup 2005 
Observational study of tardive 
dyskinesia and other side effects of 
atypical antipsychotic medications. 
MacCAT-CR. 
BIQ, PANSS, HAM-D, neurocognitive Z 
score, socio-demographics. 
Mixed inpatients and outpatients, some in board and 
care homes. Aged ≥ 40. 
Palmer 2006 
Inpatients RCT of antipsychotic medication. MacCAT-CR. BPRS, VCF. 
Long stay patients on a research ward with 
schizophrenia. 
Kovnick 2003 
Unclear 
Outpatients 
RCT of cognitive enhancement 
medication. 
 
MacCAT-CR. PANSS, MMSE, socio-demographics. Aged ≥60. Palmer 2005 
MacCAT-CR.  
Recruited before medication free period as an 
inpatient for treatment of schizophrenia.  Only data 
on correlations is effect of interventions. 
Moser 2005 
MacCAT-CR.  Only data on correlations is effect of interventions. Moser 2006 
fMRI study of decision-making 
capacity. 
MacCAT-CR. PANSS, socio-demographics. 
Outpatient study recruiting from board and care 
homes. 
Eyler 2007 
Mixed 
RCT of cognitive enhancement 
medication. 
MacCAT-CR, ESC. RBANS.  Moser 2002 
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Legend: ACCT, Assessment of Capacity to Consent to Treatment Interview, ACE, Addenbrooke’s Cognitive Exam, BDI, Beck Depression Inventory, BIQ, Birchwood Insight 
Questionnaire, BPRS, Brief Psychiatric Rating Scale, CGI, Clinical Global Impression, DRS, Mattis Dementia Rating Scale, ESC, Evaluation to Sign Consent, FAB, Frontal 
Assessment Battery, HAM-D, Hamilton Depression Rating Scale, MacCAT-CR, MacArthur Competence Assessment Tool for Clinical Research, MacCAT-T, MacArthur Competence 
Assessment Tool for Treatment, MADRS, Montgomery-Åsberg Depression Rating Scale, mESC, Modified Evaluation to Sign Consent, MMSE, Mini-Mental State Exam, PANSS, 
Positive and Negative Syndrome Scale, RBANS, Repeatable Battery for the Assessment of Neuropsychological Status, SAI, Schedule for the Assessment of Insight, SSICA, Semi-
structured inventory for competence assessment, SUMD, Scale to assess Unawareness of Mental Disorder, VCF, Verbal Cognitive Functioning. 
 
NB – many studies also reported on individual neurocognitive sub-tests from various test batteries, these are not presented in this table. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inpatients 
RCT of cognitive enhancement 
medication. 
MacCAT-CR, Clinical assessment 
of audio-tapes of MacCAT-CR but 
no absolute scores reported. 
G12 PANSS insight, PANSS, CGI, 
MMSE. 
Members of a hospital based therapeutic 
community. Stable patients. 
Lan 2013 
Unrelated Mixed 
RCT for an antibiotic for sore throat 
vs an established treatment. 
MacCAT-CR. PANSS, MMSE, socio-demographics.  Candilis 2006/08 
Two studies one 
related one not 
Inpatients 
Two studies: 1) RCT of 
antipsychotic medication; 2) 
Ketamine PET scan study. 
MacCAT-CR.   Cohen 2004 
Not reported Inpatients 
Hypothetical clinical trial – no further 
information. 
Clinical assessment (no further 
details or absolute scores 
reported), MacCAT-CR. 
FAB, ACE. Voluntary inpatients admitted for > 6 months. Linder 2012 
Four Factor 
Scores & Expert 
Judgement 
Unclear Outpatients 
RCT of cognitive enhancement 
medication. 
MacCAT-CR, clinical assessment 
based on reviewing the MacCAT-
CR records using the criteria of the 
four factor model. 
PANSS, HAM-D, RBANS, socio-
demographics. 
Outpatients aged >40. Jeste 2009 
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Table 2 Summary of DMC-T studies with a binary outcome of DMC-T 
 
Study  DMC 
Standard 
Decision 
assessed 
Setting Other relevant features Total study 
N 
n with 
DMC-T 
Proportion with 
DMC-T (95CI) 
Weinstock 
1984 
Clinical Unrelated 
medical 
treatment 
N/A Medically unwell in a physical health 
hospital referred for determination of 
DMC-T for medical treatment 
N=2 n=2 1 (0.34-1) 
Veliz 1987 Clinical Related 
psychiatric 
treatment 
Inpatients Referred to the Court for 
determination of lack of competency 
to refuse or consent to treatment 
forensic population 
N=35 n=4 0.11 (0.05-0.26) 
Bean 1994 Clinical Related 
psychiatric 
treatment 
Inpatients Inpatients requiring ECT N=32 n=19 0.59 (0.42-0.75) 
Wong 
2000 
Clinical Blood test  - 
unclear degree 
related 
Mixed  N=21 n=19 0.90 (0.71-0.97) 
Bellhouse 
2003 
Clinical Related 
psychiatric 
treatment 
Inpatients  N=9 n=6 0.67 (0.35-0.88) 
Vollmann 
2003 
Clinical Related 
psychiatric 
treatment 
Inpatients No detained patients. N=43 n=35 0.81 (0.67-0.90) 
Moye 2008 Threshold Unrelated 
medical 
treatment 
Outpatients > 60 years old. N=20 n=4 0.2 (0.08-0.42) 
Cairns 
2005 
Clinical Related 
psychiatric 
treatment 
Inpatients  N=62 n=30 0.48 (0.36-0.61) 
Owen 
2009/11 
Clinical Related 
psychiatric 
treatment 
Inpatients  N=93 n=24 0.26 (0.18-0.36) 
Di 2013 Threshold Related 
psychiatric 
treatment 
Inpatients Guardian also needed to agree in 
order to participate in study. 
N=192 n=138 0.72 (0.65-0.78) 
Skipworth 
2013 
Clinical Related 
psychiatric 
treatment 
Mixed Mixed inpatients and outpatients 
under forensic services 
N=97 n=63 0.65 (0.55-0.74) 
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Table 3 – Associations with DMC-T and DMC-R 
 
Associations with DMC-T in red, DMC-R in black 
 
 Associated with lack of DMC / 
worse performance on dimension 
scores 
No association Associated with presence of DMC / 
better performance on dimension 
scores 
Effect Size 
(cohen’s d) 
L M S  S M L 
 ≥ 0.5 < 0.5 < 0.3  0 < 0.3 < 0.5 ≥ 0.5 
Lack of insight 
P A R 
 
U A R C  
P* 
 
U A R 
U  
U A R CC 
   
PANSS Total 
UU 
 
U A R  
UU A  
 
R 
AA RR CC  
U A R CC  
   
PANSS General 
U  
U A R  
 
U A C 
 
UU A R C 
U AA RR CC  
P* UU A RR C 
   
PANSS +VE  
U 
A R  
 
U A 
UUU AAAA RRRR CCC  
P* UUUUUU AAA RRRR CCCC  
   
PANSS –VE 
U  
U A  
UU  
U A R  
 
UU A R C 
U AAAA RRRR CCC  
P* UUU AA RRR CCC 
   
BPRS 
 
U A 
P U 
R  
 
 
UU AAA RRR CC  
P U A R C 
   
Affective symptoms    
UUU AAA RRR CC  
P* UU A R C  
   
Higher neurocognitive 
performance 
   
AA  
P AA RRRR CCCCC 
U A RR  
UU RR C  
P**P* UUU AA  
 
UUUUU AAA RR 
Older age   R 
PP UUUUU AAAAA RRRRR CCCC 
P* UUUUUU AAAA RRR CCC 
   
Male gender    
PP UU AA RR CC 
UUU AA RR C 
   
Black and minority 
ethnicity 
  
 
A R 
UU AA RR CC  
UU A R C 
   
Higher socio-
economic status 
   
A 
 
R 
 
U 
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Each letters symbolises an individual study finding an association, with horizontal position on the table representing direction of association and 
effect size.  Individual letters represent the DMC standard the association was found with: P, association with binary outcome of DMC; U, 
association with ‘understanding’; A, association with ‘appreciation’; R, association with ‘reasoning’; C, association with ‘expressing a choice’.   
* Dunn 2007 used three standards as their binary outcome so the ‘most’ standard was selected as this required scoring in ‘understanding’, 
‘appreciation’, and ‘reasoning’, rather than the other two standards which just required scores in ‘understanding’.  Dunn also used two presented 
data on two summary summary neurocognitive scores (DRS and a neurocognitive z score), the neurocognitive z score is presented here. 
** Linder 2012 presented data on two summary neurocognitive scores (FAB positive association of medium ES, ACE no association), the FAB 
score is reported here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
More years of 
education 
   
P UU AAAAA RRRR CCCC  
P* UUU A RR CCC 
R  
U A RR 
UU  
UA 
P U  
A 
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Supplemental table 1 summary data and characteristics of all studies 
 
 
 
 
Title Setting  
 
 
Study N  
 
 
n with DMC 
 
 
Proportion (95 
Cis)  
 
 Lack of 
Insight 
PANSS  (Total (T), General (G), 
Positive (+VE). Negative (-VE) 
BPR
S  
Affective 
symptoms 
Neurocognitive 
performance 
(unless stated z score) 
Socio-Demographics Education (y) 
 DMC R or T Tool Used 
 
Nature of decision   T G +VE -VE      
Specific Issues and other results Measur
e 
correlat
ed 
against 
          
                
Weinstock 
1984 
N/A N=2 n=2 1 (0.34-1) 
P - - - - - - - - - -  DMC-T C Unrelated medical treatment 
Specific features:  Medically unwell in a physical health hospital referred for determination of 
DMC-T for medical treatment 
                
Veliz 1987 Inpatients N=35 n=4 0.11 (0.05-0.26) 
P - - - - - - - - - -  DMC-T C Related psychiatric treatment  
Specific features:  Referred to the Court for determination of lack of competency to refuse or 
consent to treatment forensic population     
                
Bean 1994 Inpatients N=32 n=19 0.59 (0.42-0.75) 
P - - - - - - - - - -  DMC-T C Related psychiatric treatment  
Specific features:  Inpatients requiring ECT     
                
Wong 2000 Mixed N=21 n=19 0.90 (0.71-0.97) 
P - - - - - - - - - - 
 DMC-T C Blood test  - unclear degree related  
                
Bellhouse 
2003 
Inpatients N=9 n=6 0.67 (0.35-0.88) 
P - - - - - - - - - - 
 DMC-T C Related psychiatric treatment  
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Moye 2008 Outpatients N=20 n=4 0.2 (0.08-0.42) P - - - - - - - - - - 
 DMC-T 
‘ACCT’ 
interview 
assessing 
four factor 
model with 
cut off 
Unrelated medical treatment U - - - - - - - - - -  
Specific features:  ≥ 60 years old. 
Other results: U 'rate of impairment' 35%, A 'rate of impairment' 55%, R rate of 'impairment' 
45%, C 'rate of impairment' 40% 
A - - - - - - - - - -     
R - - - - - - - - - -    
C - - - - - - - - - - 
                
Skipworth 
2013 
Mixed N=97 n=63 0.65 (0.55-0.74) P - - - - - - - - - - 
 DMC-T C, M-T Related psychiatric treatment U - - - - - - - - - - 
Specific features:  Mixed inpatients and outpatients under forensic services 
A - - - - - - - - - - 
R - - - - - - - - - - 
C - - - - - - - - - -  
                
Vollmann 
2003 
Inpatients N=43 n=35 0.81 (0.67-0.90) P - - - - - - - - 0 age*, 0 gender* 0* 
 DMC-T C, M-T Related psychiatric treatment U - - - - - - - - - - 
Specific features:  No detained patients. 
Other results: ‘Impairment standard’ requiring understanding D and T>4; reasoning >3; AD 
and AT >0.  If not then meet ‘impairment standard’.  In this sample n=23 had impairment 
using this standard. 
*against 'impairment standard' 
A - - - - - - - - - -    
R - - - - - - - - - -    
C - - - - - - - - - - 
                
Cairns 2005 Inpatients N=62 n=30 0.48 (0.36-0.61) P - - - - - - - - - - 
 DMC-T C, M-T Related psychiatric treatment U - - - - - - - - - -  
     A - - - - - - - - - - 
     R - - - - - - - - - - 
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     C - - - - - - - - - - 
                
Owen 2009/11 Inpatients N=93 n=24 0.26 (0.18-0.36) P -L SAI - - - - -M - - - - 
 DMC-T C, M-T Related psychiatric treatment U - - - - - - - - - - 
 
A - - - - - - - - - -    
R - - - - - - - - - -    
C - - - - - - - - - - 
                
Di 2013 Inpatients N=192 n=138 0.72 (0.65-0.78) P - - - - - * - - 0 age, 0 gender 
+L 7 - 9 years, 
+L 10-12, +M 
>12 (reference 
< 7 years) 
 DMC-T 
‘SSICA’ 
interview 
assessing 
four factor 
model with 
cut off 
Related psychiatric treatment U - - - - - - - - - - 
Specific features:  Guardian also needed to agree in order to participate in study. 
* Data reported uninterpretable. 
A - - - - - - - - - -    
R - - - - - - - - - -    
     C - - - - - - - - - - 
                
Grisso 
1995/95 
Inpatients N=75 n/a n/a U - - - - - -M* - +M VCF* +M SES* ** 
 DMC-T 
M-T 
precursors 
Related psychiatric treatment A - - - - - 0* - 0 VCF* 0 SES* ** 
Specific features:  Clinicians requested severely unwell people to not be recruited  
Other results: 48.1% demonstrated adequate performance across measures of U, A, and R 
(C not included) judged by an arbitrary cut-off but the authors clearly state they do not 
consider this to equate to a lack of DMC-T. BPRS factor 3 (thought disorganisation) - M for 
U. 
*Several individual tools were used to measure each domain of U, A, R, and C.  The authors 
interpreted presence of at least one statistically significant association with a tool within a 
domain as sufficient to demonstrate association, strongest associations reported here. 
**Included in SES 
R - - - - - 0* - +M VCF* +S SES* ** 
C - - - - - - - - - - 
                
Grisso 1997 Inpatients N=40 n/a n/a U - - - - - 0 - - 0 age, 0 gender, 0 race 0 
 DMC-T M-T Related psychiatric treatment A - - - - - 0 - - 0 age, 0 gender, 0 race 0 
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R - - - - - 0 - - 0 age, 0 gender, 0 race 0 
C - - - - - 0 - - 0 age, 0 gender, 0 race 0 
                
Palmer 2004 Outpatients N=59 n/a n/a U - - - 0 0 0 - +M DRS  0 age, 0 gender, 0 race 0 
 DMC-T M-T Related psychiatric treatment A - - - 0 0 0 - 0 DRS 0 age, 0 gender, 0 race 0 
Specific features:  Outpatients, although most living at community assisted living facilities, 
age ≥ 40. 
R - - - 0 0 0 - +M DRS 0 age, 0 gender, 0 race 0 
     C - - - 0 0 0 - +M DRS 0 age, 0 gender, 0 race 0 
                
Koren 2005 Inpatients N=21 n/a n/a U - - - - - - - - - - 
 DMC-T M-T Related psychiatric treatment A - - - - - - - - - -  
Specific features:  Within two weeks of admission when clinician has determined them able 
to cooperate. 
(data only presented as individual cognitive sub-scale scores) 
R - - - - - - - - - -     
C - - - - - - - - - -    
                
Wong 2005 Inpatients N=81 n/a n/a U 
-M G12 
PANSS 
-L - -M -M - 
0 
MADRS 
- 0 age +L 
 DMC-T M-T Related psychiatric treatment A 
-M G12 
PANSS 
-M - 0 0 - 
0 
MADRS 
- 0 age 0 
Specific features:  Before discharge from hospital 
Other results: 0 on side effect measures and U,A,R; with U drug attitude 0; with drug attitude 
inventory 0; with R drug attitude inventory +S (greater score on drug attitude = more 
complaint with medication) 
R 
-M G12 
PANSS 
-M - 0 0 - 
0 
MADRS 
- 0 age +S 
C - - - - - - - - - - 
                
Capdevielle 
2009 
Outpatients N=60 n/a n/a U 0 SUMD* -M 0 0 -M - 0 BDI - 0 age +M 
 DMC-T M-T Related psychiatric treatment A 
-L 
SUMD* 
0 0 0 0 - 0 BDI - 0 age 0 
Specific features: Treatment not changed for past month 
Other results: All 0 for anxiety scores (state and trait) and U,A,R,C 
*Summary SUMD score was not provided, rather a breakdown of the five components of the 
SUMD and their correlations.  The authors interpreted presence of at least one statistically 
significant association as sufficient to demonstrate association (for A and R there were 
associations with all 5 components, with C only 2). 
R 
-L 
SUMD* 
0 0 0 0 - 0 BDI - 0 age 0 
C 
-M 
SUMD* 
0 0 0 0 - 0 BDI - 0 age 0 
                
Raffard 2013 Outpatients N=60 n/a n/a U - -L -L 0 -L - 0 BDI - 0 age +M 
 DMC-T M-T Related psychiatric treatment A - 0 0 0 0 - 0 BDI - 0 age 0 
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Specific features:  Treatment not changed for past month 
Other results: All 0 for anxiety scores (state and trait) and U,A,R,C; BCIS 'self reflectiveness) 
+ M with R, all other BCIS and U,A,R,C correlations 0 
R - 0 0 0 0 - 0 BDI - 0 age 0 
C - 0 0 0 0 - 0 BDI - 0 age 0 
                
Norko 1990 Inpatients N=22 n/a n/a 
Minim
um 
- - - - - - - - - - 
 DMC-T 
Tool 
assessing 
4 factor 
model 
Related psychiatric treatment  Broad - - - - - - - - - -  
Specific features:  No detained patients 
Other results: Proportion meeting standards: minimum, 80%, Broad 75%, Legal 45%, 
Combined 63% 
Legal - - - - - - - - - -     
Comb
ined 
- - - - - - - - - -    
                
Chiu 2014 Inpatients N=17 n/a n/a Not relevant. 
 DMC-T C Related psychiatric treatment            
Specific features: People having ECT without consent 
Other results: n=13 0.76 (0.53-0.90) of those having ECT without consent lacked DMC-T 
           
                
Jeste 2009 Outpatients N=66  
0.47 (only a sub-
portion had the 
clinical scores) 
P - - - - - - - - - - 
 DMC-R 
M-CR, C 
assessmen
t involving 
review of 
M-CR 
records* 
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
U - 0 0 0 0  0 HAM-D +L RBANS 0 age, 0 gender -  
Specific features:  Outpatients aged >40 
*The UBACC (University of California San Diego Brief Assessment for Capacity to Consent) 
tool was also used but data not extracted to prevent repetition of data presented from the 
same sample. 
A - - - - - - - - - -     
R - - - - - - - - - - 
C - - - - - - - - - - 
                
Carpenter 
2000 
Mixed N=30 n/a n/a U - - - - - 0 - +L RBANS - - 
 DMC-R M-CR 
Hypothetical RCT of antipsychotic 
medication related to disorder 
A - - - - - 0 - 0 RBANS - - 
Other results: with U and BPRS Factor 1 ‘psychosis factor’ –M; with A and BPRS Factor 1 –
M; with R and BPRS Factor 1 –L; with C and BPRS Factor 1 0  
R - - - - - -M - +L RBANS - - 
 Page 44 of 47 
 
C - - - - - 0 - 0 RBANS - - 
                
Moser 2002 Mixed N=25 n/a n/a U - - - - - * - +L RBANS - - 
 DMC-R M-CR, ESC 
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
A - - - - - * - +L RBANS - - 
Specific features: Mixed outpatients and inpatients, some recruited from a mental health 
research centre. 
Other results: With U SANS/SAPS –VE -L, disorganized -M, psychotic  0; With A 
SANS/SAPS –VE 0, disorganized -L, psychotic 0; with R SANS/SAPS –VE -L, disorganized -
M, psychotic 0; * reported in regression analysis but not as individual bivariate correlations 
R - - - - - * - 0 RBANS - - 
C - - - - - - - - - - 
                
Kovnick 2003 Inpatients N=27 n/a n/a U - - - - - -L - +L VCF - - 
 DMC-R M-CR 
Hypothetical RCT of antipsychotic 
medication related to disorder 
A - - - - - -L - +L VCF - - 
Specific features: Long stay patients on a research ward with schizophrenia 
Other results: With U BPRS Subscales Psychoticism -M, withdrawal -L; depression and 
hostility 0; With A BPRS Subscales Depression -M, withdrawal -L; hostility and psychoticism 
0; With R BPRS Subscales, psychoticism , depression, withdrawal, hostility all 0 
R - - - - - 0 - 0 VCF - - 
C - - - - - - - - - - 
                
Cohen 2004 Inpatients N=6 n/a n/a U - - - - - - - - - - 
 DMC-R M-CR 
Hypothetical decision about involvement 
in research, one study treatment related 
to disorder, the other is an imaging study 
using ketamine  
 
A - - - - - - - - - -  
Specific features: Results of the study dichotmised by willingness to participate.  Only 
presented proportion data on MacCAT-CR scores for willing and unwilling people by study 
Other results: Scores on the MacCAT-CR were not associated with a willingness to 
participate. 
 
R - - - - - - - - - -     
C - - - - - - - - - -    
                
Palmer 2005 Outpatients N=35 n/a n/a U - - - 0 0 - - +M MMSE 0 age 0 
 DMC-R M-CR*  
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
A - - - 0 0 - - 0 MMSE 0 age +L 
Specific features: All clinically stable outpatients recruited through clinical research 
programmes at the university.  Aged ≥60 
* The three item questionnaire tool was also used but data not extracted to prevent repetition 
of data presented from the same sample. 
R - - - 0 0 - - 0 MMSE 0 age 0 
C - - - 0 0 - - 0 MMSE 0 age 0 
                
Stroup 2005 Mixed N=1447 n/a n/a U - - -S 0 -S - - +S  
0 age, 0 gender, 0 ‘non-
white’ 
+S 
 DMC-R M-CR 
Real decision about involvement in a 
naturalistic treatment trial related to their 
disorder. 
A - - -S 0 -S - - +S 
0 age, 0 gender, -S 
‘non-white’ 
+S 
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Specific features: Mixed inpatients and outpatients already recruited to the CATIE study 
(having suboptimal antipsychotic treatment) and passing a MacCAT-CR based DMC-R 
threshold (U ≥ 16).  
R - - 0 0 -S - - +S 
-S age, 0 gender, -S 
‘non-white’ 
+S 
C - - - - - - - - - - 
                
Candilis 
2006/08 
Mixed N=52 n/a n/a U - -M -L 0 -L - - +L MMSE 0 age, 0 gender, 0 race +M 
 DMC-R M-CR 
Hypothetical decision about an RCT 
using antibiotics for sore throats, 
unrelated to their disorder. 
A - 0 -L -M -L - - +L MMSE 0 age, 0 gender, 0 race +M 
Other results: With U SF36 physical functioning +M; With A SF36 physical functioning +L; 
With R SF36 physical functioning +M; with C SF36 physical functioning 0 
R - 0 -L -M 0 - - +L MMSE 0 age, 0 gender, 0 race +S 
C - 0 -M 0 0 - - 0 MMSE 0 age, 0 gender, 0 race 0 
                
Palmer 2006 Mixed N=70 n/a n/a U 0 BIQ - -S 0 -M - 0 HAM-D +M 0 age 0 
 DMC-R M-CR 
Real decision about observational study 
of side effects related to their treatment 
with antipsychotics related to their 
disorder 
A 0 BIQ - 0 0 0 - 0 HAM-D +M 0 age 0 
Specific features: Mixed inpatients and outpatients, some in board and care homes. Aged 
≥40 
R 0 BIQ - 0 0 0 - 0 HAM-D 0 0 age 0 
C 0 BIQ - -S 0 0 - 0 HAM-D 0 0 age 0 
                
Dunn 2007 Mixed N=91 n/a n/a 1 -M BIQ - 0 0 -S - 0 HAM-D 0, 0 DRS  0 age 0 
 DMC-R M-CR 
Hypothetical RCT of antipsychotic 
medication related to disorder 
2 -S BIQ - -M 0 -M - 0 HAM-D +M, +M DRS 0 age +S 
Specific features: Mixed outpatient and inpatients, including board and care homes, aged 
≥50.  Data analysed by standards of thresholds on sub-scale scores. 
Other results: Standard 1:Least U>15, proportion=0.923; Standard 2:Intermediate U≥20, 
proportion =0.813; Standard 3:Most U≥18, A≥5, R≥6, proportion=0.429 
3 -M BIQ - 0 0 0 - 0 HAM-D +M, 0 DRS 0 age 0 
                
Eyler 2007 Outpatients N=14 n/a n/a U - - 0 0 0 - - - 0 age 0 
 DMC-R M-CR 
Real decision about recruitment into an 
fMRI observational study that is not clear 
if relevant to that disorder. 
A - - - - - - - - - - 
Specific features: Outpatient study recruiting from board and care homes 
R - - - - - - - - - -    
C - - - - - - - - - -    
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Linder 2012 Inpatients N=21 Not reported  P - - - - - - - +M FAB, 0 ACE - - 
 DMC-R C, M-CR 
Hypothetical ‘clinical 
trial’ no further 
information. 
 U - - - - - - - - - - 
Specific features: Voluntary inpatients admitted for > 6 months 
Other results: MacCAT-CR total and FAB +L; MacCAT-CR total and ACE +L 
A - - - - - - - - - -  
 
R - - - - - - - - - -     
C - - - - - - - - - -    
                
Lan 2013 Inpatients N=139 n/a n/a U 
-S G12 
PANSS 
-M -M -S -S - - +M MMSE - - 
 DMC-R C*, M-CR 
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
A 
-S G12 
PANSS 
-M -M -S -M - - +M MMSE - - 
Specific features: Members of a hospital based therapeutic community. Stable patients. 
Other results: With U CGI 0; With A CGI –S; With R CGI – S; With C CGI 0.   
*’Brief judgement score’ of clinicians assessment of audio-interviews also used but no 
absolute scores reported or tested for correlations of variables of interest. 
R 
-S G12 
PANSS 
-S -S 0 -M - - +S MMSE - - 
C 
0 G12 
PANSS 
0 0 0 -S - - 0 MMSE - - 
                
Fischer 2013 Outpatients N=59 n/a n/a 
mES
C 
- - - - - 0 - 0 - - 
 DMC-R mESC 
Real decision about involvement in an 
RCT related to their disorder 
Specific features: Already recruited to the parent study, all data is for baseline 
Other results: BPRS negative 0, BPRS psychosis 0 (both at baseline testing); compared 
research experience group with non-research experience and no significant difference 
between scores 
                
Eyler 2005 Outpatients N=44 n/a n/a 
Only presents % score data and correlations with interventions  DMC-R M-CR 
Decision about involvement in an fMRI 
study on DMC-R in Schizophrenia 
(related) 
Specific features: Outpatient study recruiting from board and care homes 
                
Moser 2005 Outpatients N=10 n/a n/a 
Only data on correlations is effect of interventions (medication free period)  DMC-R M-CR 
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
Specific features: People admitted for monitoring during the course of a medication free 
period during a study. 
                
Moser 2006 Outpatients N=30 n/a n/a Only data on correlations is effect of interventions (educational) 
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 DMC-R M-CR 
Hypothetical decision about an unclearly 
related RCT (cognition enhancing drug) 
Specific features: Mixed inpatients and outpatients involved in research programmes 
                
 
 
Key 
 
Tool Used: 
 
 Other: 
 
 
ACCT Assessment of Capacity to Consent to Treatment Interview (Factor scores) ACE  Addenbrooke’s Cognitive Exam 
C Clinical Assessment (Judgement standard) AD  Appreciation Disorder 
ESC Evaluation to Sign Consent (Cut off standard) AT  Appreciation Treatment 
M-CR MacCAT-CR (Factor scores) BDI  Beck Depression Inventory 
M-T  MacCAT-T (Factor scores) BIQ  Birchwood Insight Questionnaire 
  BPRS  Brief Psychiatric Rating Scale 
Measure of DMC  CGI  Clinical Global Impression 
 DRS Mattis Dementia Rating Scale 
P  Proportion with DMC FAB  Frontal Assessment Battery 
U  Understanding HAM-D  Hamilton Depression Rating Scale 
A  Appreciation MADRS  Montgomery-Åsberg Depression Rating Scale 
R  Reasoning MMSE  Mini-Mental State Exam, 
C Expressing a Choice PANSS  Positive and Negative Syndrome Scale 
  RBANS  Repeatable Battery for the Assessment of Neuropsychological Status 
Measures of 
association 
 SAI  Schedule for the Assessment of Insight 
 SES  Socio-Economic Status 
S Small effect size SUMD Scale to assess Unawareness of Mental Disorder  
M Medium effect size VCF  Verbal Cognitive Functioning 
L Large effect size   
0 No association found/not significant   
- Not measured   
 
 
 
 
 
 
 
 
 
 
